Abstract 'Glomerulonephritis'(GN) is a term used to describe a group of heterogeneous
immune-mediated disorders characterized by inflammation of the filtration units of the kidney …

Secondary immunodeficiency is reported in most patients with hematological malignancies
such as chronic lymphocytic leukemia and multiple myeloma. The aim of our review was to …

The life of every organism is dependent on the fine-tuned mechanisms of protein synthesis
and breakdown. The degradation of most intracellular proteins is performed by the ubiquitin …

Over 2 decades ago, the proteasome was considered a risky or even untenable therapeutic
target. Today, proteasome inhibitors are a mainstay in the treatment of multiple myeloma …

Simple Summary Multiple myeloma is a malignant neoplasm of plasma cells with complex
pathogenesis. With major progresses in multiple myeloma research, it is essential that we …

Defective autophagy is linked to proinflammatory diseases. However, the mechanisms by
which autophagy limits inflammation remain elusive. Here, we found that the pan-FGFR …

Multiple myeloma (MM) is a genetically heterogeneous disease that includes a subgroup of
10–15% of patients facing dismal survival despite the most intensive treatment. Despite …

Proteasome inhibitors have been actively tested as potential anticancer drugs and in the
treatment of inflammatory and autoimmune diseases. Unfortunately, cells adapt to survive in …

Proteasomes are broadly expressed key components of the ubiquitin-dependent protein
degradation pathway containing catalytically active subunits (β1, β2, and β5). LMP7 (β5i) is …

The cepafungins are a class of highly potent and selective eukaryotic proteasome inhibitor
natural products with potential to treat refractory multiple myeloma and other cancers. The …